On June 28, 2021, a novel oral drug- 2-deoxy-D-glucose (2-DG) was commercially unveiled by a leading pharmaceutical- Dr. Reddy’s Laboratories. As mentioned, Dr. Reddy will provide this medicine to the leading government and private hospitals all over India. Initially, the organization will make the drug available in hospitals in metros and Tier 1 cities (Delhi, Mumbai, Chennai, Kolkata, Bangalore, Hyderabad, Ahmedabad and Pune), and eventually expand its coverage to the remaining regions.

2-DG will be sold under the brand name 2DG^TM with a purity of 99.5%. For the government institutes, a subsidized price has been offered. This drug is a result of a fruitful outcome of Institute of Nuclear Medicine & Allied Sciences (INMAS) and Dr. Reddy's Lab.

It can only be used in hospitalized people suffering from moderate to severe COVID-19 as an add-on therapy to the prevailing standard care as recommended and under the guidance of an experienced doctor. On May 1, 2021, this medicine was given as emergency use authorization for anti-COVID-19 treatment by the Drugs Controller General of India (DCGI). This launch marks 2-DG as yet another milestone in the fight against infectious coronavirus disease (COVID-19).